Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04558918
Other study ID # CLNP023C12302
Secondary ID 2019-004665-40
Status Completed
Phase Phase 3
First received
Last updated
Start date January 25, 2021
Est. completion date March 6, 2023

Study information

Verified date February 2024
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was a multi-center, randomized, open-label, active comparator-controlled, parallel group study. The purpose of this Phase 3 study in PNH patients presenting with residual anemia despite treatment with anti-C5 antibody, was to determine whether iptacopan is efficacious and safe for the treatment of PNH through demonstration of superiority of iptacopan compared to anti-C5 antibody treatment.


Description:

The study comprised three periods: - A screening period lasting up to 8 weeks (unless there was a need to extend it for vaccinations required for inclusion, vaccinations were started as early as possible to avoid extension of the screening period) - A 24-week randomized, open-label, active controlled, treatment period for the primary efficacy and safety analyses. Patients who met the eligibility criteria at screening were stratified based on the type of prior anti-C5 antibody treatment (eculizumab or ravulizumab) and based on the transfusion history as reported during the last 6 months prior to randomization (i.e. transfusion received/not received). Patients were randomized to one of the two treatment groups in an 8:5 ratio to either iptacopan monotherapy at a dose of 200 mg orally b.i.d. or i.v. anti-C5 antibody treatment (patients continued with the same regimen during the randomized treatment period as they were prior to randomization), respectively. - A 24-week open-label, iptacopan treatment extension period. The patients randomized to the active comparator group were offered to switch to iptacopan on Day 168 (Week 24 visit) and entered the treatment extension period, after receiving a last dose of anti-C5 antibody treatment (eculizumab or ravulizumab). For patients in the comparator group not agreeing to switch treatment, Week 24 visit was the End of Study visit for the trial with no participation in the treatment extension period. For patients agreeing to switch to oral iptacopan, the Extension treatment started on the day after completion of the Week 24 visit. The patients in the iptacopan group who, in the opinion of investigator, benefitted from treatment and were taking iptacopan at Week 24 visit (i.e. did not permanently discontinue study medication), were offered the opportunity to continue oral iptacopan treatment during the treatment extension period. - Data cut-off date used for the primary results submission was 26- Sep-2022


Recruitment information / eligibility

Status Completed
Enrollment 97
Est. completion date March 6, 2023
Est. primary completion date September 26, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male and female participants = 18 years of age with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size = 10% - Stable regimen of anti-C5 antibody treatment (either eculizumab or ravulizumab) for at least 6 months prior to randomization - Mean hemoglobin level <10 g/dL - Vaccination against Neisseria meningitidis infection is required prior to the start of treatment. - If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given Exclusion Criteria: - Participants on a stable eculizumab dose but with a dosing interval of 11 days or less or patients on stable ravulizumab dose but with a dosing interval of less than 8 weeks. - Known or suspected hereditary complement deficiency at screening - History of hematopoietic stem cell transplantation - Patients with laboratory evidence of bone marrow failure (reticulocytes <100x10E9/L; platelets <30x10E9/L; neutrophils <500x10E6/L). - Active systemic bacterial, viral (incl. COVID-19), or fungal infection within 14 days prior to study drug administration - A history of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus. - Major concurrent comorbidities including but not limited to severe kidney disease (e.g., eGFR < 30 mL/min/1.73 m2, dialysis), advanced cardiac disease (e.g., NYHA class IV), severe pulmonary disease (e.g., severe pulmonary hypertension (WHO class IV)), or hepatic disease (e.g., active hepatitis) that in the opinion of the investigator precludes participant's participation in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LNP023
Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
Eculizumab
Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose. Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion
Ravulizumab
Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight. Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion

Locations

Country Name City State
Brazil Novartis Investigative Site Santo Andre SP
Brazil Novartis Investigative Site Sao Paulo SP
Czechia Novartis Investigative Site Ostrava Poruba
France Novartis Investigative Site Lille
France Novartis Investigative Site Paris 10
France Novartis Investigative Site Toulouse
Germany Novartis Investigative Site Aachen
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Riesa
Germany Novartis Investigative Site Ulm
Italy Novartis Investigative Site Ascoli Piceno AP
Italy Novartis Investigative Site Avellino AV
Italy Novartis Investigative Site Bassano Del Grappa VI
Italy Novartis Investigative Site Firenze FI
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Torino TO
Japan Novartis Investigative Site Fukushima city Fukushima
Japan Novartis Investigative Site Kanazawa-city Ishikawa
Japan Novartis Investigative Site Kyoto
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Shinjuku-ku Tokyo
Japan Novartis Investigative Site Suita Osaka
Japan Novartis Investigative Site Suwa Nagano
Korea, Republic of Novartis Investigative Site Seoul
Netherlands Novartis Investigative Site Nijmegen
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site San Sebastian Pais Vasco
Spain Novartis Investigative Site Santiago De Compostela Galicia
Taiwan Novartis Investigative Site Hualien
Taiwan Novartis Investigative Site Taipei
United Kingdom Novartis Investigative Site Leeds
United Kingdom Novartis Investigative Site London
United States Augusta University Georgia Patient Treatment Augusta Georgia
United States Levine Cancer Insitute Carolinas Healthcare System Charlotte North Carolina
United States Cleveland Clinic Foundation Dept.ofTaussigCancer Center Cleveland Ohio
United States City Of Hope National Med Center City of Hope Medical Center Duarte California
United States Univ Cali Irvine ALS Neuromuscular Orange California

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Brazil,  Czechia,  France,  Germany,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Change From Baseline in Absolute Reticulocyte Count at Day 336 Change from baseline in absolute reticulocyte count at visit Day 336. Patients randomized to anti-C5 antibody were switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period). Baseline and Day 336
Other Ratio to Baseline in Log-transformed LDH at Visit Day 336 Average of the Lactate dehydrogenase (LDH) log transformed ratio to baseline at visit Day 336.The log transformation used refers to the natural log (base of e).
Patients randomized to anti-C5 treatment switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period).
Baseline and Day 336
Primary Marginal Proportion (Expressed as Percentages) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of = 2 g/dL in the Absence of Red Blood Cell Transfusions Sustained increase in hemoglobin levels (responder) is defined as an increase from baseline in hemoglobin levels = 2 g/dL on three out of four measurements taken at the visits occurring in last six weeks (between Day 126 and 168) of the randomized treatment period, without requiring red blood cell (RBC) transfusions between Day 14 and Day 168. Requiring RBC transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level = 9 g/dL with signs /and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of = 7 g/dL, regardless of presence of clinical signs and/or symptoms).
The term 'marginal proportion' can be interpreted as the population average probability of being a responder for each treatment group. These values include adjustment for baseline covariates and missing data has also been taken into account.
Baseline, hemoglobin between Day 126 and Day 168 and absence of transfusions between Day 14 and Day 168
Primary Marginal Proportion (Expressed as Percentages) of Participants With Sustained Hemoglobin Levels of = 12 g/dL in the Absence of Red Blood Cell Transfusions Sustained hemoglobin levels (responder) is defined as hemoglobin levels = 12 g/dL on three out of four measurements taken at the visits occurring in last six weeks (between Day 126 and 168) of the randomized treatment period, without requiring red blood cell (RBC) transfusions between Day 14 and Day 168. Requiring RBC transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level = 9 g/dL with signs /and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of = 7 g/dL, regardless of presence of clinical signs and/or symptoms).
The term 'marginal proportion' can be interpreted as the population average probability of being a responder for each treatment group. These values include adjustment for baseline covariates and missing data has also been taken into account.
Hemoglobin between Day 126 and Day 168 and absence of transfusions between Day 14 and Day 168
Primary Percentage of Patients Meeting Hematological Response Criterion After the Start of LNP023 Treatment Patients with hematological response are those with = 2g/dL increase in hemoglobin from baseline regardless of transfusions and patients with Hb = 12g/dL regardless of transfusions.
Patients in the LNP023-LNP023 group received iptacopan from Day 1 to Day 336 (48 weeks) while patients in the anti-C5 antibody-LNP023 group received iptacopan from Day 169 to Day 336 (treatment extension period - 24 weeks).
Up to 48 weeks
Primary Number of Patients Not Requiring RBC Transfusions After the Start of LNP023 Treatment Requiring RBC transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level = 9 g/dL with signs /and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of = 7 g/dL, regardless of presence of clinical signs and/or symptoms).
Patients randomized to anti-C5 treatment switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period).
Up to 48 weeks
Primary Change From Baseline in Hemoglobin at Visit Day 336 Patients randomized to anti-C5 treatment switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period). Baseline, Day 336
Primary Change From Baseline in FACIT-Fatigue Questionnaire at Day 336 The FACIT-Fatigue is a 13-item questionnaire with support for its validity and reliability in PNH that assesses patient self-reported fatigue and its impact on daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F Scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.
Patients randomized to anti-C5 treatment switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period).
Baseline, Day 336
Primary Adjusted Annualized Clinical BTH Rate After the Start of LNP023 Treatment This endpoint is considering clinical BTH events after the start of LNP023 treatment. Therefore, results are presented in a single arm on LNP023 since it includes all patients in the Combined Full analysis set.
Adjusted annualized rate of clinical breakthrough hemolysis (BTH) events are from negative binomial model. A patient with multiple occurrences of an event under one treatment is counted only once for that treatment.The breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment, or within 15 days) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs & symptoms, in presence of laboratory evidence of intravascular hemolysis.
Up to 336 Days
Primary Adjusted Annualized Major Adverse Vascular Events Rate After the Start of LNP023 Treatment This endpoint is considering clinical BTH events after the start of LNP023 treatment. Therefore, results are presented in a single arm on LNP023 since it includes all patients in the Combined Full analysis set.
Adjusted annualized Major Adverse Vascular Events (MAVEs incl. thrombosis) rate. A MAVE is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial, thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other.
A patient with multiple occurrences of an event under one treatment is counted only once for that treatment.
Up to 336 Days
Secondary Marginal Proportion (Expressed as Percentages) of Participants Who Remain Free From Transfusions Marginal proportion (expressed as percentages) of participants who did not require transfusions between Day 14 and Day 168. Requiring red blood cell transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level = 9 g/dL with signs /and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of = 7 g/dL, regardless of presence of clinical signs and/or symptoms). The term 'marginal proportion' can be interpreted as the population average probability of being a responder for each treatment group. These values include adjustment for baseline covariates and missing data has also been taken into account. Between Day 14 and Day 168
Secondary Change From Baseline in Hemoglobin Between Day 126 and 168 Change from baseline in hemoglobin levels as mean of visits between Day 126 and Day 168.
For this analysis, in order to factor out the effect of transfusions, if a patient had a transfusion during the randomized treatment period, then the hemoglobin values 30 days following the transfusion were excluded and hemoglobin data were imputed.
Baseline and mean of visits between Day 126 and 168
Secondary Change From Baseline in FACIT-Fatigue Questionnaire in the Randomized Treatment Period The FACIT-Fatigue is a 13-item questionnaire with support for its validity and reliability in PNH that assesses patient self-reported fatigue and its impact on daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F Scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best. Baseline, mean of visits between Day 126 and Day 168
Secondary Change From Baseline in Absolute Reticulocyte Count in the Randomized Treatment Period Change from baseline in absolute reticulocyte count as mean of visits between Day 126 and Day 168 Baseline and mean of visits between Day 126 and 168
Secondary Ratio to Baseline in Log-transformed LDH in the Randomized Treatment Period Average of the Lactate dehydrogenase (LDH) log transformed ratio to baseline in each treatment estimated between Day 126 and Day 168.The log transformation used refers to the natural log (base of e). Baseline and mean of visits between Day 126 and 168
Secondary Adjusted Annualized Clinical BTH Rate in the Randomized Treatment Period Adjusted annualized rate of clinical breakthrough hemolysis (BTH) events are from negative binomial model.
A patient with multiple occurrences of an event under one treatment is counted only once for that treatment.
The breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment, or within 15 days) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs & symptoms, in presence of laboratory evidence of intravascular hemolysis.
Between Day 1 and Day 168
Secondary Adjusted Annualized Major Adverse Vascular Events Rate in the Randomized Treatment Period Adjusted annualized Major Adverse Vascular Events (MAVEs incl. thrombosis) rate. A MAVE is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial, thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other.
A patient with multiple occurrences of an event under one treatment is counted only once for that treatment.
Between Day 1 and Day 168
See also
  Status Clinical Trial Phase
Completed NCT00004143 - Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Phase 2
Terminated NCT05116787 - BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy Phase 2
Recruiting NCT06294301 - A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants Phase 1
Completed NCT03472885 - Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab Phase 2
Completed NCT03946748 - Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Enrolling by invitation NCT03427060 - Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms Phase 2
Completed NCT03078582 - Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Phase 2
Completed NCT03053102 - Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Not yet recruiting NCT06312644 - Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Completed NCT03588026 - Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 Phase 3
Completed NCT03056040 - ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Phase 3
Completed NCT00145613 - Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Phase 2
Completed NCT00587054 - Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Phase 2
Recruiting NCT05876312 - Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Phase 1
Completed NCT04820530 - Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy Phase 3
Terminated NCT03225287 - Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study Phase 2
Completed NCT02352493 - A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH Phase 1/Phase 2
Recruiting NCT04901936 - A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT02264639 - A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH Phase 1
Recruiting NCT03520647 - Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis Phase 2